Cilengitide

Generic Name: Cilengitide

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₀N_₈O_₇

CAS Number: 188968-51-6

Unique Ingredient Identifier: 4EDF46E4GI

Background: Cilengitide has been used in trials studying the treatment of Sarcoma, Gliomas, Lymphoma, Leukemia, and Lung Cancer, among others.

Clinical Trials

EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer

Phase 1

Completed

Conditions: Leukemia
Precancerous/Nonmalignant Condition
Small Intestine Cancer
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Unspecified Adult Solid Tumor, Protocol Specific
Chronic Myeloproliferative Disorders

First Posted Date: 2004-07-26

Last Posted Date: 2014-09-17

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 40

Registration Number: NCT00004258

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Drug: cilengitide
Drug: temozolomide
Radiation: radiation therapy
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2004-06-11

Last Posted Date: 2016-02-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 112

Registration Number: NCT00085254

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 5 locations

EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma

Phase 1

Terminated

Conditions: Sarcoma

Interventions: Drug: cilengitide

First Posted Date: 2004-05-26

Last Posted Date: 2013-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00006222

Locations: 🇺🇸
Vanderbilt Cancer Center, Nashville, Tennessee, United States
🇺🇸
University of California San Diego Cancer Center, La Jolla, California, United States
🇺🇸
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States

Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma

Phase 2

Terminated

Conditions: Stage III Melanoma
Stage IV Melanoma

Interventions: Drug: cilengitide
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2004-05-19

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 56

Registration Number: NCT00082875

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: AIDS-related Peripheral/Systemic Lymphoma
AIDS-related Primary CNS Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Intraocular Lymphoma
Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma

Interventions: Drug: cilengitide

First Posted Date: 2004-02-11

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00077155

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Cilengitide in Treating Children With Refractory Primary Brain Tumors

Phase 1

Completed

Conditions: Childhood Central Nervous System Germ Cell Tumor
Childhood Choroid Plexus Tumor
Childhood Craniopharyngioma
Childhood Ependymoblastoma
Childhood Grade I Meningioma
Childhood Grade II Meningioma
Childhood Grade III Meningioma
Childhood High-grade Cerebellar Astrocytoma
Childhood High-grade Cerebral Astrocytoma
Childhood Infratentorial Ependymoma

Interventions: Drug: cilengitide
Other: laboratory biomarker analysis

First Posted Date: 2003-07-09

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00063973

Locations: 🇺🇸
Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States

EMD 121974 in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: cilengitide
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00022113

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States

EMD 121974 in Treating Patients With Progressive or Recurrent Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-24

Lead Sponsor: New Approaches to Brain Tumor Therapy Consortium

Registration Number: NCT00006093

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy